文摘
摘要目的:确定因素预测术前癫痫的发生(PRS)和术后癫痫(POS)在胶质母细胞瘤(GBM)患者。
背景:癫痫在GBM患者描述,尽管在一个较低的频率比低级别胶质瘤。尽管最近的研究表明epileptogenesis更多的与遗传分子标记在低品位glioma-related发作,信息因素影响GBM-related PRS和POS的发展缺乏。
设计/方法:我们进行了单中心回顾性队列研究GBM患者评估的梅奥诊所佛罗里达,2018年和2022年之间。临床因素,包括肿瘤分子标记、神经生理学和影像学表现进行分析根据PRS和POS的状态。
结果:一百三十二成人患者(平均年龄= 61.5年),79(59.85%)的女性)被包括在内。最常见的位置是颞(n = 50, 42.02%)和额叶(n = 47岁的39.50%)。所有患者接受GBM切除术,17.1%接受切除(n = 22)。六十二名患者(46.27%)接受了术中electrocorticography在GBM切除。异柠檬酸脱氢酶1 (IDH1)有野生型121例(90.3%),61例O6-methylguanine-DNA甲基转移酶(管理)甲基化“绿带运动”(46.21%)。40例(33.9%)有PRS, 39名患者(38.24%)有POS(平均随访= 17.27个月;差= 10.6 - -30.1)。IDH1野生型和管理甲基化状态与PRS没有关联或POS。PRS患者年轻(59年和64年,p = 0.021),经历了一个较长的生存时间(16.1个月和8.3个月,p = 0.044没有PRS)相比,病人。枕叶GBM PRS的可能性(较低有关p = 0.043)和POS (p = 0.001)。
结论:PRS与年轻和更长的生存时间相关。PRS和POS和枕叶不太可能发生肿瘤。还需要进一步的研究来证实我们的发现和阐明的影响其他肿瘤分子标记的发展PRS和POS GBM患者。
披露:桑切斯博士Boluarte没有披露。加西亚博士没有披露。Gunasekera博士没有披露。泰特姆博士已经收到个人薪酬在10000 - 49999美元的范围为Bioserenity担任顾问。泰特姆博士已经收到个人薪酬在500 - 4999美元的范围作为一个编辑,副主编,或为爱思唯尔编辑顾问委员会成员。泰特姆博士已经收到个人薪酬在500 - 4999美元的范围作为专家证人的辩护律师事务所代表与基金捐赠给癫痫患者癫痫的基础。泰特姆博士的机构已经接到Esai研究支持。泰特姆博士的机构已经收到了来自梅奥诊所的研究支持。泰特姆博士的机构收到Liva新星的研究支持。泰特姆博士的机构已经接到从事药品研究支持。 The institution of Dr. Tatum has received research support from Xenon. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurelis. Dr. Sirven has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Sirven has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Sirven has stock in Doximity. Dr. Sirven has received publishing royalties from a publication relating to health care. Dr. Sirven has a non-compensated relationship as a Host with WJCT Public Media/ NPR that is relevant to AAN interests or activities. Dr. Freund has nothing to disclose. The institution of Dr. Ritaccio has received research support from NIH. Dr. Ritaccio has received intellectual property interests from a discovery or technology relating to health care. Kaisorn Chaichana has nothing to disclose. Alfredo Quiñones-Hinojosa has nothing to disclose. Dr. Feyissa has nothing to disclose.
